JP2017526924A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526924A5
JP2017526924A5 JP2017511945A JP2017511945A JP2017526924A5 JP 2017526924 A5 JP2017526924 A5 JP 2017526924A5 JP 2017511945 A JP2017511945 A JP 2017511945A JP 2017511945 A JP2017511945 A JP 2017511945A JP 2017526924 A5 JP2017526924 A5 JP 2017526924A5
Authority
JP
Japan
Prior art keywords
nep
vitro
vitro method
soluble
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511945A
Other languages
English (en)
Japanese (ja)
Other versions
JP6661216B2 (ja
JP2017526924A (ja
Filing date
Publication date
Priority claimed from EP14182846.7A external-priority patent/EP2990800A1/en
Application filed filed Critical
Publication of JP2017526924A publication Critical patent/JP2017526924A/ja
Publication of JP2017526924A5 publication Critical patent/JP2017526924A5/ja
Application granted granted Critical
Publication of JP6661216B2 publication Critical patent/JP6661216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511945A 2014-08-29 2015-08-14 心不全予後マーカーとしてのネプリライシン Expired - Fee Related JP6661216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
EP14182846.7 2014-08-29
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (3)

Publication Number Publication Date
JP2017526924A JP2017526924A (ja) 2017-09-14
JP2017526924A5 true JP2017526924A5 (enExample) 2018-09-20
JP6661216B2 JP6661216B2 (ja) 2020-03-11

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511945A Expired - Fee Related JP6661216B2 (ja) 2014-08-29 2015-08-14 心不全予後マーカーとしてのネプリライシン

Country Status (11)

Country Link
US (1) US10203341B2 (enExample)
EP (2) EP2990800A1 (enExample)
JP (1) JP6661216B2 (enExample)
CN (1) CN107076758B (enExample)
AU (1) AU2015309112A1 (enExample)
CA (1) CA2959094A1 (enExample)
ES (1) ES2734876T3 (enExample)
MX (1) MX2017002453A (enExample)
RU (1) RU2017109086A (enExample)
SG (1) SG11201701393YA (enExample)
WO (1) WO2016030209A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090909A1 (ja) * 2019-11-06 2021-05-14 国立大学法人 香川大学 心不全マーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549019A (en) * 2001-09-03 2008-05-30 Intreat Pty Ltd Antibody that binds to a P2X7 receptor in which proline at position 210 is in a cis conformation
NZ599773A (en) * 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
JP5945063B2 (ja) * 2012-04-12 2016-07-05 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性心不全が疑われる患者における有害事象の予後
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014116708A1 (en) * 2013-01-22 2014-07-31 Singulex, Inc. Endothelin in the diagnosis of cardiac disease
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
NZ710574A (en) * 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors

Similar Documents

Publication Publication Date Title
Kaswala et al. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016
Zhou et al. Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis
Orasan et al. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies
JP2012509477A5 (enExample)
Shen et al. Implications of the changes in serum neutrophil gelatinase‐associated lipocalin and cystatin C in patients with chronic kidney disease
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
NO20076656L (no) Forbedrede immunoassay metoder
JP2015519564A5 (enExample)
Schuuring et al. High‐sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease
CN103403554A (zh) 慢性心力衰竭的预后和诊断方法
HRP20151023T1 (hr) Metode za detekciju protutijela na lijekove
JP2013511735A5 (enExample)
JP2017532577A5 (enExample)
JP2017505897A5 (enExample)
Nishikawa et al. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation
Gandhi et al. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure
JP2016526167A5 (enExample)
JP2009544971A5 (enExample)
JP2017524933A5 (enExample)
JP2013506837A5 (enExample)
JP2014524583A5 (enExample)
US10557860B2 (en) Circulating pulmonary hypertension biomarker
CN107255711A (zh) 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途
JP2015528562A5 (enExample)